Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

CHICAGO -- Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions. With numerous ...

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...

Lazertinib plus amivantamab was approved based on results from the phase III MARIPOSA trial, which compared the combination with osimertinib monotherapy or lazertinib monotherapy. Lazertinib plus ...

Alert FDA Expands Indication for Amivantamab in Lung Cancer Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...